Keyphrases
Intravenous Bisphosphonates
100%
Osteonecrosis of the Jaw
100%
Osteoporotic Patients
100%
Bisphosphonates
66%
Osteoporosis
50%
Older Adults
16%
Risk Factors
16%
Survival Analysis
16%
Osteoporosis Treatment
16%
National Sample
16%
Medicare Beneficiaries
16%
Inflammatory Conditions
16%
Disease Factor
16%
Total Dose
16%
Multivariable
16%
Potential Confounders
16%
Intravenous Infusion
16%
Risk Profile
16%
Bone Disease
16%
Patients with Cancer
16%
Metabolic Bone Disease
16%
Bisphosphonate Use
16%
Log-rank Test
16%
Sex Type
16%
Population-based Cohort
16%
Absolute Risk
16%
Cox Proportional Hazards Regression
16%
Bisphosphonate Therapy
16%
Toxicity Outcomes
16%
Clinical Scenarios
16%
Risk-benefit Ratio
16%
Facial Bones
16%
Medicine and Dentistry
Osteoporosis
100%
Osteonecrosis of the Jaw
100%
Bisphosphonate
100%
Jaw
40%
Proportional Hazards Model
20%
Malignant Neoplasm
10%
Medicare
10%
Serositis
10%
Intravenous Drug Administration
10%
Bone Disease
10%
Metabolic Bone Disease
10%
Risk-Benefit Ratio
10%
Log Rank Test
10%
Facial Bone
10%
Pharmacology, Toxicology and Pharmaceutical Science
Bisphosphonic Acid Derivative
100%
Jaw Osteonecrosis
100%
Malignant Neoplasm
20%
Inflammation
10%
Bone Disease
10%
Metabolic Bone Disease
10%